Yun Yun Go
Raluca Dulgheru
Patrizio Lancellotti- 1National Heart Centre Singapore, National Heart Research Institute Singapore, Singapore, Singapore
- 2Department of Cardiology, University Hospital Sart Tilman, Heart Valve Clinic, University of Liège, Liège, Belgium
- 3GIGA Cardiovascular Sciences, University Hospital Sart Tilman, Liège, Belgium
- 4Gruppo Villa Maria Care and Research, Anthea Hospital, Bari, Italy
Findings from early percutaneous tricuspid intervention trials have shown that the severity of tricuspid regurgitation (TR) far exceeded the current definition of severe TR. Also, the improvement in the amount of TR following tricuspid intervention is not accounted for by the current definition of TR as different degrees of severity at the severe end was grouped under the same umbrella term of “severe.” There has been a recent call to expand the TR grading system, encompassing two more grades, namely “massive” and “torrential” TR, in the order of increasing severity. This seems appropriate as the patients enrolled in tricuspid intervention trials were found to have TR severity up to 2 grades above the current severe thresholds of effective regurgitant orifice area (EROA) 40 mm2, regurgitant volume (R Vol) 45 ml and vena contracta (VC) width 7 mm. The proposed grade of “massive” is defined by EROA 60–79 mm2, R Vol 60–74 ml and VC 14–20 mm, while “torrential” is defined by EROA ≥80 mm2, R Vol ≥75 ml, and VC ≥21 mm. The grading of TR requires a comprehensive, multi-parametric approach. In particular, quantitative assessment of TR should be performed in patients who require serial monitoring and quantification of treatment effect.
Introduction
The tricuspid valve has often been labeled the forgotten valve, due to the lack of attention it received compared to its counterparts such as the mitral or aortic valve (1). Research interests and advancement in therapy, most notably percutaneous valve intervention for years seems to elude the tricuspid valve. In recent years, the tide appears to be turning. We witnessed a rise in interest and developmental breakthroughs in the treatment of functional or secondary tricuspid regurgitation (TR). The movement is both appropriate and timely as functional TR is a common but often-overlooked clinical problem. Severe TR is associated with increased morbidity and mortality (2, 3). Despite the poor outcomes, the number of patients with severe TR undergoing tricuspid valve surgery was dismal. Approximately 1.6 million patients in the United States live with moderate to severe TR and there are <8,000 tricuspid surgery performed annually (4, 5). The overwhelming majority of tricuspid valve surgery was performed during concomitant left-sided valve surgery (6). Among patients who underwent left-sided valve surgery, 37% eventually developed severe TR following rheumatic mitral valve replacement and 74% had moderate to severe TR 3 years after ischemic mitral repair surgery (7, 8). This not only speaks volume of the unmet need for TR treatment, but also illustrates the treatment difficulty in patients with previous left-sided heart surgery who need downstream TR intervention, either in the form of redo surgery or percutaneous therapy. Last but not least, it highlights the importance of comprehensive and methodical echocardiographic assessment prior to or following any valve surgery.
Echocardiographic Assessment of TR
Echocardiography is the imaging modality of choice to assess TR severity and in turn, help to guide decision for treatment. The guideline-recommended echocardiographic assessment of TR is, however, not without its challenges. It involves a multi-parametric approach and calls for qualitative, semi-quantitative, and quantitative evaluation (9). Qualitative and semi-quantitative assessment are relatively straightforward and intuitive as they do not require multi-step calculations as quantitative approach does. As a result, many clinicians often adopt the qualitative or semi-quantitative approach, which give rise to two problems. First, it renders most comparisons, either serially over time or between patients difficult due to the lack of precision and standardization. Second, it is prone to under-estimation of the regurgitant severity.
Traditionally, TR is graded into mild, moderate, and severe, following the severity grading conventions that also apply to mitral, aortic, and pulmonary valves. Severe TR is defined quantitatively as an effective regurgitant orifice area (EROA) of ≥40 mm2 and a regurgitant volume of ≥45 ml according to both the European Association of Cardiovascular Imaging (EACVI) and American Society of Echocardiography (ASE) recommendations (9, 10). In particular, the EACVI recommendations made provision for massive TR. Massive TR is referred to as TR that is beyond severe and it is associated with a low TR jet velocity of <2 m/s as there is near equalization of right ventricular and right atrial pressures (9). However, in the EACVI recommendations, massive TR was defined qualitatively. There were no quantitative or semi-quantitative parameters that distinguish massive from severe TR and therein lies a 2-fold problem. For starter, the distinction between severe and massive is not always clear. Qualitative parameters such as the size of the TR jet on color Doppler can change substantially according to the Nyquist limits and loading conditions. Similarly, in the case of massive TR with very large regurgitant orifice area, a distinct color jet may not be apparent due to the presence of laminar, low velocity flow (10). Also, the use of descriptive terminology without proper standardization and quantification lacks the scientific rigor necessary for quality research. Terms such as very severe, free, massive, or torrential are descriptive and thus subjected to interpretation. Loose application or interchangeable usage of these terms are not uncommon both the published literature and clinical practice, making meaningful, quantitative comparisons impossible.
“Of note, the EACVI guidelines do not recommend EROA calculation using the quantitative PW Doppler method due to the lack of evidence that supports its use in TR quantification. The quantitative Doppler method however, has been used in mitral regurgitation studies and it systematically produces a larger EROA compared to PISA-derived EROA (11). Whether these findings can be extrapolated in patients with TR and if the cut-offs for severity grading are comparable warrant further studies.”
Revision of the Current TR Grading System
In recent times, there has been a movement to revise the current TR grading, expanding the TR grading spectrum beyond severe to include “massive” and “torrential,” in ascending severity (12). There are a few impetuses to expand the existing guideline-recommended TR grading. First, the rise of percutaneous tricuspid valve intervention trials and registry saw the enrolment of patients with TR far exceeded the severe limit defined by current guidelines (13). These patients had on average, TR with VC width, EROA or regurgitant volume one to two grades above the current definition of severe. Such magnitude calls to question the adequacy of the current definition at depicting the complete clinical picture. The lack of further distinction at the extreme end of the TR spectrum not only leads to non-discriminatory treatment of TR with different severity and prognosis, but also makes treatment effect difficult to detect. Natural history studies have shown that patients' prognosis worsened as the severity of TR increases, supporting the case for grading TR beyond severe to reflect the differential outcomes. This is particularly relevant among patients who received percutaneous TV interventions. After all, it is challenging to explain to patients that a therapy which improves their TR from severe to severe might still benefit them.
Some percutaneous TR intervention trials that included sick patients with torrential TR reported improvement in TR parameters equivalent to one full grade reduction or 20 mm2 in terms of EROA (13, 14). There was also improvement in measurable clinical outcomes such as New York Heart Association (NYHA) class, quality of life and 6-min walk test. Although there was a lack of head-to-head comparison with patients treated with medical therapy alone in these trials, it is not unreasonable to associate these improvements with the reduction of EROA, reduction in tricuspid annulus size and increase in forward stroke volume, as a result of the intervention.
In the SCOUT (Percutaneous Tricuspid Valve Annuloplasty System for Symptomatic Chronic Functional Tricuspid Regurgitation) trial, the average quantitative EROA of the cohort was 85 mm2 (13), which is more than 2 grades above the existing severe threshold of 40 mm2, assuming a grade difference of 20 mm2. Also, the average vena contracta (VC) of the SCOUT cohort was 13 mm, which is ~2 grades above the existing severe threshold of 7 mm, assuming a grade difference of 3–4 mm. The transcatheter plication system produced a reduction of quantitative EROA of >20 mm2, more than a full grade reduction of TR, which was both statistically significant and clinically meaningful. In the International Multicentre TriValve Registry, the average tricuspid EROA was 87 ± 56 mm2 and the average regurgitant volume was 63 ml, while the average VC was 11 mm (14), all at 1–2 grades above the current thresholds for severe TR, defined as EROA of 40 mm2, regurgitant volume of 45 ml and VC of 7 mm.
The argument for the expansion of the current TR grading system stems primarily, although not solely, from the growing need to standardize and quantify transcatheter tricuspid treatment effect. With no specific criteria that capture the disease severity at the tail end of the TR spectrum, there is a risk of diluting measurable treatment effect. Currently, procedural success is defined as residual TR of ≤2+, successful implantation of device and patients being alive at the end of the procedure, similar to the definition used in mitral valve intervention. Only 62% of patients in the International Multicentre TriValve Registry achieved procedural success by definition and 51% of patients still had ≥3+ TR on discharge echocardiography. There was however, significant improvement in NYHA functional class and reduction in diuretic requirement at 30 days (14). The absence of a detailed grading system to quantify treatment effect may account for the discrepancy between the lack of significant TR grade reduction and the improvement of quality of life following successful percutaneous TV intervention.
It is inevitable that an improved TR grading system will be needed in view of the inadequacy of current definition. Table 1 illustrates a proposed grading system, with emphasis on a systematic, multi-parametric approach. Table 2 summarizes the improvements made in the new grading system compared to the current guidelines. It must be mentioned that the proposed TR grading system is based mainly on data gathered from percutaneous tricuspid intervention studies, which tend to be modest in study size and highly selective. The grading system therefore requires further refinement and support from large natural history, registry or outcome studies.
Table 1. Proposed tricuspid regurgitation grading.
Table 2. Comparisons of current guideline vs. proposed changes to TR grading.
“In summary, there is no easy solution to the TR grading conundrum. Perhaps one that come close is to place heavier emphasis on quantitative assessment of TR. In the context of tricuspid valve intervention, this can be carried out by routinely report the EROA before and after the procedure in terms of absolute or percentage change. An alternative, as proposed by Han et al. would be to expand the current grading system linearly by adding two more grades beyond the current definition of severe TR. More data, especially long-term outcome data is needed to resolve the conundrum.”
Conclusion
TR has a wide disease spectrum, especially toward the severe end. A grading approach that emphasize on quantitative assessment account for the granularity of disease and give equal weightage to the full disease spectrum. It incorporates our new understanding of baseline TR severity and make allowance for measurable TR reduction in the era of percutaneous tricuspid intervention. It also introduces checks and balances, moving from subjective definition to a standardized lingo. In the foreseeable future, it is likely to have an influence on and in turn, be influenced by the design and evaluation of tricuspid interventional trials.
Author Contributions
All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The reviewer NB and handling Editor declared their shared affiliation.
References
1. Lancellotti P, Fattouch K, Dulgheru R. Targeting the tricuspid valve: a new therapeutic challenge. Arch Cardiovasc Dis. (2016) 109:1–3. doi: 10.1016/j.acvd.2015.11.001
2. Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol. (2004) 43:405–9. doi: 10.1016/j.jacc.2003.09.036
3. Topilsky Y, Nkomo VT, Vatury O, Michelena HI, Letourneau T, Suri RM, et al. Clinical outcome of isolated tricuspid regurgitation. JACC Cardiovasc Imaging (2014) 7:1185–94. doi: 10.1016/j.jcmg.2014.07.018
4. Stuge O, Liddicoat J. Emerging opportunities for cardiac surgeons within. J Thorac Cardiovasc Surg. (2006) 132:1258–61. doi: 10.1016/j.jtcvs.2006.08.049
5. Zack CJ, Fender EA, Chandrashekar P, Reddy YNV, Bennett CE, Stulak JM, et al. National trends and outcomes in isolated tricuspid valve surgery. J Am Coll Cardiol. (2017) 70:2953–60. doi: 10.1016/j.jacc.2017.10.039
6. Kilic A, Saha-Chaudhuri P, Rankin JS, Conte JV. Trends and outcomes of tricuspid valve surgery in north america: an analysis of more than 50,000 patients from the society of thoracic surgeons database. Ann Thorac Surg. (2013) 96:1546–52. doi: 10.1016/j.athoracsur.2013.06.031
7. Izumi C, Iga K, Konishi T. Progression of isolated tricuspid regurgitation late after mitral valve surgery for rheumatic mitral valve disease. J Heart Valve Dis. (2002) 11:353–6.
8. Matsunaga A, Duran CM. Progression of tricuspid regurgitation after repaired functional ischemic mitral regurgitation. Circulation (2005) 112:1453–7. doi: 10.1161/CIRCULATIONAHA.104.524421
9. Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Pierard LA, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging (2013) 14:611–44. doi: 10.1093/ehjci/jet105
10. Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. (2017) 30:303–71. doi: 10.1016/j.echo.2017.01.007
11. Thavendiranathan P, Phelan D, Thomas JD, Flamm SD, Marwick TH. Quantitative assessment of mitral regurgitation: validation of new methods. J Am Coll Cardiol. (2012) 60:1470–83. doi: 10.1016/j.jacc.2012.05.048
12. Hahn RT, Zamorano JL. The need for a new tricuspid regurgitation grading scheme. Eur Hear J Cardiovasc Imaging (2017) 18:1342–3. doi: 10.1093/ehjci/jex139
13. Hahn RT, Meduri CU, Davidson CJ, Lim S, Nazif TM, Ricciardi MJ, et al. Early feasibility study of a transcatheter tricuspid valve annuloplasty: SCOUT trial 30-day results. J Am Coll Cardiol. (2017) 69:1795–806. doi: 10.1016/j.jacc.2017.01.054
Keywords: tricuspid regurgitation grading, massive tricuspid regurgitation, torrential tricuspid regurgitation, echocardiography, percutaneous intervention
Citation: Go YY, Dulgheru R and Lancellotti P (2018) The Conundrum of Tricuspid Regurgitation Grading. Front. Cardiovasc. Med. 5:164. doi: 10.3389/fcvm.2018.00164
Received: 11 June 2018; Accepted: 22 October 2018;
Published: 09 November 2018.
Edited by:
Fabien Praz, Universitätsspital Bern, SwitzerlandReviewed by:
Nicolas Brugger, Universitätsspital Bern, SwitzerlandPatric Bîaggi, Heart Clinic Zurich, Switzerland
Copyright © 2018 Go, Dulgheru and Lancellotti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Patrizio Lancellotti, cGxhbmNlbGxvdHRpQGNodS51bGcuYWMuYmU=